Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Dry Eye Disease
Interventions: ALY688 0.1%, ALY688 0.4%, Vehicle; Drug
Lead sponsor: Allysta Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bellevue, Washington

Conditions: Multiple Sclerosis
Interventions: Activity Monitoring and Symptom Coaching, Passive Activity Monitoring; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pmm2-CDG, Phosphomannomutase 2 Deficiency, Phosphomannomutase 2 Congenital Disorder of Glycosylation, Phosphomannomutase II Congenital Disorder of Glycosylation, Phosphomannomutase II Deficiency
Interventions: Epalrestat, Placebo; Drug
Lead sponsor: Maggie's Pearl, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Proctitis, Proctosigmoiditis
Interventions: Budesonide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 62
States / cities: Dothan, Alabama • Mesa, Arizona • Tucson, Arizona + 59 more

Conditions: Hepatitis C, Chronic, Hepatitis C
Interventions: GSK625433/placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Pneumococcal Vaccines
Interventions: 24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • DeLand, Florida • Hollywood, Florida + 17 more

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP); Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 6
States / cities: New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more

Conditions: Colonoscopy, Mass Screening
Interventions: Mailed educational brochure; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older
Enrollment: 628 participants
Timeline: 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Asthma
Interventions: MN-221, Placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: Loma Linda, California • San Diego, California • Sylmar, California + 11 more

Conditions: Systemic Sclerosis, Pulmonary; Hypertension
Interventions: Dimethyl Fumarate (DMF), Placebo Oral Tablet; Drug
Lead sponsor: Robert Lafyatis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Diabetes, Hypertension, Hyperlipidemia, Heart Diseases, Depression, Psychoses
Interventions: pharmacist contact with the patient via telephone, Pharmacist contact with the patient's physician via fax, Usual care; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: Not listed
Enrollment: 3,048 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Escherichia Infection
Interventions: B7A (ETEC challenge strain), CssBA, dmLT, Placebo; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Hereditary Sensory and Autonomic Neuropathy Type I
Interventions: L-serine, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts • Worcester, Massachusetts

Conditions: Mycobacterium Infections, Nontuberculous
Interventions: Liposomal amikacin for inhalation (LAI), placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 18
States / cities: Birmingham, Alabama • Stanford, California • Denver, Colorado + 15 more

Conditions: Prostate Cancer
Interventions: tasquinimod, Placebo; Drug
Lead sponsor: Active Biotech AB; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 34
States / cities: Tucson, Arizona • Oxnard, California • Santa Monica, California + 31 more

Conditions: Parkinson Disease
Interventions: Multimodal Exercise Program with Gamification; Other
Lead sponsor: California State University, Northridge; Other
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Ventura, California

Conditions: Sleep Deprivation
Interventions: Controlled Dietary Intervention; Drug
Lead sponsor: St. Vincent's Medical Center; Other
Eligibility: 25 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Sclerosis, Scleroderma
Interventions: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 1 more

Conditions: Opioid Pain Medication
Interventions: Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin, Lidocaine Hydrochloride with Epinephrine, Bupivacaine Hydrochloride with Epinephrine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Disease
Interventions: Methotrexate, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4,786 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 404
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 296 more

Conditions: Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma
Interventions: Biological G207; Biological
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 3 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 5
States / cities: Aurora, Colorado • New York, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Benzodiazepine Dependence, Opioid Dependence
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Long Island City, New York

Conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678 250 mg, Placebo, JNJ-53718678 125 mg; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Los Angeles, California • Detroit, Michigan • Minneapolis, Minnesota + 6 more

Search by objective public record fields.

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Coaching and Activity Tracking in Multiple Sclerosis - A Pilot Study

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

RCT of Mailed Brochure to Boost Adherence to Screening Colonoscopy

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Pharmacy Interventions to Improve Chronic Disease Medication Refill

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)

A Change in Diet May Decrease the Negative Consequences of Chronic Sleep Deprivation

Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis

Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

Cardiovascular Inflammation Reduction Trial

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients

Intravenous Ketamine for Treatment-Resistant Depression

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)